MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

Home・Aktien・Cogent Biosciences Inc

Cogent Biosciences Inc

Geschlossen

38.75 -0.21

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

38.75

Max

38.75

Schlüsselkennzahlen
By Trading Economics
Einkommen	-7.4M -81M
EPS	-0.5
Angestellte	205
EBITDA	-6.8M -79M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+29.04% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	24. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	3.2B 5.3B
Vorheriger Eröffnungskurs	38.96
Vorheriger Schlusskurs	38.75

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

4.88 / 5.87 Unterstützung & Widerstand

Cogent Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

19. Jan. 2026, 16:17 UTC

Akquisitionen, Fusionen, Übernahmen

Zurich Insurance Makes $10 Billion Bid for U.K. Specialist Insurer Beazley -- Update

19. Jan. 2026, 23:50 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over U.S.-Europe Relations -- Market Talk

19. Jan. 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

19. Jan. 2026, 22:29 UTC

Market Talk

China Infant Formula Market May Hold Up Despite Steep Drop in Births -- Market Talk

19. Jan. 2026, 22:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19. Jan. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

19. Jan. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

19. Jan. 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

19. Jan. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

19. Jan. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

19. Jan. 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

19. Jan. 2026, 17:09 UTC

Market Talk

Global Equities Roundup: Market Talk

19. Jan. 2026, 17:09 UTC

Market Talk

Copper Rises in Spite of Softer Dollar, Trade Concerns -- Market Talk

19. Jan. 2026, 16:18 UTC

Market Talk

New Zealand Dollar Could Recover Against Swedish Krona -- Market Talk

19. Jan. 2026, 16:12 UTC

Market Talk

Norwegian Krone's Recent Gains Are Unlikely to Last -- Market Talk

19. Jan. 2026, 16:06 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH: Deal Completion Subject to Customary Closing Conditions and Expected to Close in Around Two Months

19. Jan. 2026, 16:04 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH: Both Parties Aim to Set Up Strategic Cooperation in the Retail Sector

19. Jan. 2026, 16:03 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH, CTG Duty-Free Also Entered Into a MoU

19. Jan. 2026, 16:02 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH: Subscription to Be Made Upon Completion of Transaction

19. Jan. 2026, 16:00 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH: Capital Increase by Subscribing to Newly Issued H-shares Listed in Hong Kong

19. Jan. 2026, 16:00 UTC

Market Talk

Term Premium on U.S. Treasurys Looks Too Low, Says Pictet AM -- Market Talk

19. Jan. 2026, 15:58 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH and the Miller Family Will Participate in a Capital Increase of CTG DutyFree

19. Jan. 2026, 15:57 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH: DFS Will Continue to Operate Its Other Luxury Travel Retail Operations Worldwide

19. Jan. 2026, 15:57 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH: Proceeds of Transaction Will Be Paid in Cash

19. Jan. 2026, 15:56 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH: CTG Duty-Free Will Run the Acquisition Through Its Subsidiary China Duty Free International Limited

19. Jan. 2026, 15:53 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH: Intangible Assets Include a Series of DFS Brands and IP for Exclusive Use in Greater China

19. Jan. 2026, 15:52 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH: CTG Duty-Free to Acquire the DFS Retail Stores in Hong Kong and Macau and Intangible Assets

19. Jan. 2026, 15:51 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH: DFS, CTG Duty-Free Reach Definitive Pact for CTG Duty-Free to Buy DFS' Travel Retail Unit in Hong Kong and Macau and Intangible Assets in Greater China

19. Jan. 2026, 15:39 UTC

Market Talk

Canadian Dollar's Underperformance Looks Overstretched -- Market Talk

19. Jan. 2026, 15:37 UTC

Market Talk

Bank of Canada Could Consider Cutting Rates if Underlying Inflation Slows Further -- Market Talk

Peer-Vergleich

Kursveränderung

Cogent Biosciences Inc Prognose

Kursziel

By TipRanks

29.04% Vorteil

12-Monats-Prognose

Durchschnitt 50.25 USD 29.04%

Hoch 67 USD

Tief 34 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cogent Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

13 ratings

Buy

Halten

Sell

Basierend auf 13 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cogent Biosciences Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

4.88 / 5.87Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.